Dundee, UK – Tay Therapeutics is proud to announce the launch of its new spin-out company, Hawkhill Therapeutics Ltd, marking a significant step forward in our mission to deliver transformative medicines for diseases of high unmet need.

Born from Tay’s deep scientific expertise and commitment to innovation, Hawkhill Therapeutics will focus on developing first-in-class therapies for obesity and metabolic health. The company will leverage cutting-edge science to address one of the most pressing global health challenges, with a particular emphasis on oral, muscle-sparing obesity treatments.

“This new spin-out reflects our strategy of building focused, high-impact medicines,” said Dr. Andrew Woodland, CEO of Tay Therapeutics and Director of Hawkhill Therapeutics. “Hawkhill will allow us to expand our reach into metabolic health while Tay continues to advance our world-leading small-molecule oral gene therapy for rare genetic diseases.”

Tay Therapeutics remains dedicated to progressing its readthrough gene therapy platform, which is currently ready for IND-enabling studies and actively seeking licensing partners. This platform is designed to restore functional proteins in patients with rare genetic disorders, all through a convenient oral delivery.

The launch of Hawkhill Therapeutics marks a major milestone in Tay’s growth and underscores our commitment to building a pipeline of life-changing medicines across multiple therapeutic areas.

🔗 See our LinkedIn announcement: TayLinkedIn